MRNA - CureVac: Wait For Concrete News Before Investing

• In the same way as Moderna and BioNTech, CureVac makes use of mRNA to develop COVID vaccines.
• However, in contrast to these two illustrious peers which are at commercialization stage, CureVac's first generation vaccine candidate has exhibited a much lower efficiency against infection.
• Following the August 31 update on CVnCoV, the biotech still makes for an investment case as it is developing a second generation vaccine and is also diversified on cancer cures.
• The cash position is also good.
• However, in view of past deceptions around efficacy, it is better to wait for concrete news before purchasing the stock.

For further details see: